10-Day Decitabine Versus Intensive Chemotherapy Followed By Transplantation in Fit AML Patients Aged ≥60 Years: Health-Related Quality of Life Outcomes of the Randomized Phase III Trial AML21 of the EORTC Leukemia Group, Gimema, Celg, and Gmds-SG / Efficace, F., Huls, G.A., Kicinski, M., Van Der Velden, W.J., Noppeney, R., Chantepie, S., Griskevicius, L., Neubauer, A., Audisio, E., Luppi, M., Fuhrmann, S., Foà, R., Crysandt, M., Gaidano, G., Vrhovac, R., Venditti, A., Posthuma, E.F.M., Candoni, A., Baron, F., Legrand, O., et al.. - In: BLOOD. - ISSN 0006-4971. - 140:Supplement 1(2022), pp. 1281-1283. [10.1182/blood-2022-166544]
10-Day Decitabine Versus Intensive Chemotherapy Followed By Transplantation in Fit AML Patients Aged ≥60 Years: Health-Related Quality of Life Outcomes of the Randomized Phase III Trial AML21 of the EORTC Leukemia Group, Gimema, Celg, and Gmds-SG
Luppi, Mario;Candoni, Anna;
2022
Pubblicazioni consigliate
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris
